Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: haloperidol Clear all
Completed No phase listed Observational

Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation

NCT03211897
View directory record Official record
Conditions
Agitation,Psychomotor
Interventions
Haloperidol Injection, Ziprasidone Injection, OLANZapine Injection, Midazolam injection
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
737 participants
Timeline
2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2018 · Synced Oct 17, 2026, 11:17 AM EDT
Recruiting Phase 4 Interventional

Haloperidol for Pain Control in Patients With Acute Musculoskeletal Back Pain in the Emergency Department

NCT06395428
View directory record Official record
Conditions
Back Pain, Chronic Pain
Interventions
Haloperidol, Ketorolac Tromethamine
Drug
Lead sponsor
Western Michigan University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 17, 2026, 11:17 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

NCT01949662
View directory record Official record
Conditions
Advanced Cancers
Interventions
Lorazepam, Placebo, Haloperidol decanoate, Questionnaires
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 17, 2026, 11:17 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Haldol/Diphenhydramine Versus Metoclopramide/Diphenhydramine for Treatment of Acute Headache in the ED: A RCT

NCT02098499
View directory record Official record
Conditions
Migraine Headaches, Nausea, Restlessness
Interventions
Haloperidol, Metoclopramide 10mg, Diphenhydramine
Drug
Lead sponsor
United States Naval Medical Center, Portsmouth
Federal
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 17, 2026, 11:17 AM EDT
Completed Phase 4 Interventional Results available

A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room

NCT00457366
View directory record Official record
Conditions
Agitation
Interventions
Quetiapine, Haloperidol, Lorazepam, Cogentin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 60 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 17, 2026, 11:17 AM EDT
Completed Phase 2 Interventional

Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone

NCT00361166
View directory record Official record
Conditions
Schizophrenia
Interventions
ACP-103
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
11
States / cities
Cerritos, California • Garden Grove, California • Glendale, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2007 · Synced Oct 17, 2026, 11:17 AM EDT
Completed Phase 4 Interventional

Treatment of Behavioral Symptoms in Alzheimer's Disease

NCT00009217
View directory record Official record
Conditions
Alzheimer's Disease, Psychosis, Agitation
Interventions
Haloperidol-Haloperidol, Haloperidol-Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
50 Years to 95 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Oct 17, 2026, 11:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy

NCT00399776
View directory record Official record
Conditions
Adolescent Depression
Interventions
Bone Density Test
Radiation
Lead sponsor
Creighton University
Other
Eligibility
10 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 4, 2011 · Synced Oct 17, 2026, 11:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Brain Networks and Addiction Susceptibility

NCT01924468
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Oral methylphenidate and Oral haloperidol
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 17, 2026, 11:17 AM EDT
Completed Phase 2 Interventional

The MIND Study: Modifying the INcidence of Delirium

NCT00096863
View directory record Official record
Conditions
Delirium, Cognition Disorders
Interventions
Ziprasidone, Haloperidol, Placebo
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
5
States / cities
Iowa City, Iowa • Chapel Hill, North Carolina • Greensboro, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 17, 2026, 11:17 AM EDT
Terminated Phase 3 Interventional Results available

Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis

NCT05065567
View directory record Official record
Conditions
Cyclic Vomiting Syndrome
Interventions
Droperidol, Haloperidol, Ondansetron 8mg
Drug
Lead sponsor
Corewell Health South
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Saint Joseph, Michigan
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 17, 2026, 11:17 AM EDT
Completed Phase 3 Interventional

Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department

NCT07246187
View directory record Official record
Conditions
Cannabinoid Hyperemesis Syndrome
Interventions
Olanzapine 10 milligram, Haloperidol
Drug
Lead sponsor
Mercy Bon Secours Saint Vincent Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 17, 2026, 11:17 AM EDT
Completed Phase 4 Interventional

Treatment of Obsessive-Compulsive Disorder

NCT00000373
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
olanzapine + fluoxetine, placebo + fluoxetine
Drug
Lead sponsor
University of Florida
Other
Eligibility
14 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2003
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 27, 2013 · Synced Oct 17, 2026, 11:17 AM EDT
Completed Phase 3 Interventional

Agitation in Alzheimer's Disease

NCT00000179
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Trazodone, Haloperidol
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 11:17 AM EDT
Completed Phase 4 Interventional

Haloperidol for the Treatment of Nausea and Vomiting in the ED

NCT04764344
View directory record Official record
Conditions
Vomiting, Nausea, Abdominal Pain, Cannabis Use
Interventions
Haloperidol, Ondansetron
Drug
Lead sponsor
Western Michigan University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 17, 2026, 11:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

NCT02431702
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Aripiprazole, Haloperidol, Olanzapine, Oral Paliperidone ER, Perphenazine, Quetiapine, Oral Risperidone, Paliperidone Palmitate Injection (PP1M), Paliperidone Palmitate Injection (PP3M)
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 35 Years
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
34
States / cities
Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 17, 2026, 11:17 AM EDT
Completed Phase 2 Interventional

Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9

NCT00000274
View directory record Official record
Conditions
Cocaine-Related Disorders, Substance-Related Disorders
Interventions
Flupenthixol
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 17, 2026, 11:17 AM EDT
Completed Not applicable Interventional Results available

Pharmacological Management of Delirium

NCT00842608
View directory record Official record
Conditions
Delirium, Cognitive Impairment
Interventions
Reduced exposure to anticholinergics, Reduced exposure to benzodiazepines, Haloperidol, Usual care
Behavioral · Procedure · Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 17, 2026, 11:17 AM EDT
Completed Phase 3 Interventional Results available

The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study

NCT01211522
View directory record Official record
Conditions
Delirium, Impaired Cognition, Long Term Psychologic Disorders
Interventions
Haloperidol, Ziprasidone, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
16
States / cities
Denver, Colorado • New Haven, Connecticut • Indianapolis, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 17, 2026, 11:17 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression

NCT00340379
View directory record Official record
Conditions
Affective Disorders
Interventions
Ziprasidone, Sertraline, Haloperidol
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Oct 17, 2026, 11:17 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

NCT03743649
View directory record Official record
Conditions
Delirium, Locally Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
Interventions
Haloperidol, Lorazepam, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Houston, Texas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 17, 2026, 11:17 AM EDT
Completed Not applicable Interventional

Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder

NCT00018642
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
quetiapine, haloperidol decanoate
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 17, 2026, 11:17 AM EDT
Completed Not applicable Interventional Results available

Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic

NCT01152697
View directory record Official record
Conditions
Patient Noncompliance
Interventions
haloperidol decanoate, haloperidol, Customized Adherence Enhancement
Drug · Behavioral
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Oct 17, 2026, 11:17 AM EDT